Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss What is the role for Immunotherapy in Relapsed Small Cell Lung Cancer after ASCO 2017?

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Emerging Options for Malignant Pleural Mesothelioma.

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Continuing Immunotherapy Beyond Progression.

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss What is PFS2 in Advanced NSCLC, and Should we Care? A Unique Analysis of the KEYNOTE-024 Trial.

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss: Keytruda is Now Approved in Combination with Chemo for Advanced Non-Squamous NSCLC

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC: New Option or Too Little Too Late?

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Improved Progression-Free Survival with Iressa as Adjuvant Therapy for EGFR Mutation Positive Patients.

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Are MET Mutations Now a Mutation We Should Look for in Lung Cancer?

One of the more eagerly awaited clinical trials in lung cancer this year is the PointBreak study that tried to identify whether an Alimta (pemetrexed)-based first line and maintenance chemo strategy is significantly superior to a well-established standard first line and maintenance therapy regimen.  Specifically, this trial randomized 939 chemo-naive patients wi